CD34 and Miyoshi myopathy: Of the patients in the MM cohort treated with plerixafor, 15/15 (100%) in the pegfilgrastim group and 18/19 patients (94.7%) in the filgrastim group achieved a CD34-positive cell count ≥ 2 × 106/kg, compared with 14/14 (100%) and 11/11 patients (100%), respectively, in those who did not receive plerixafor concomitantly before the achievement of the primary endpoint.